Eplerenone nanoemulsions for treatment of hypertension. Part II: Physical stability assessment and in vivo study
Graphical abstract
Introduction
Management of hypertension can be possible by using several remedies such as beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and aldosterone antagonists. These remedies can be administrated to patients as a combination therapy or monotherapy [1,2]. Eplerenone (EP) is an aldosterone antagonist drug which is commonly used for hypertension and chronic heart failure [3,4]. EP selectively binds to mineralocorticoid receptors. Thus, it is also called as mineralocorticoid receptor antagonist. EP has a less affinity to androgenic receptors and glucocorticoid receptors due to its selectivity on mineralocorticoid receptors. Therefore, it reduces the risk of gynecomastia, menstrual irregularities and sexual dysfunction. Although the adverse effects of EP are rarely seen, hyperkalemia is one of remarkable side effects that may result in arrhythmias [5,6].
EP is a class II drug according to the biopharmaceutical classification system (BCS) which means EP has a low aqueous solubility and high permeability [7]. Low soluble drugs are potential candidates for lipid based drug delivery systems which are suitable carriers for increasing drug bioavailability and achieving more efficient therapy [8,9]. Nanoemulsions (NEs) have been used for purposes of parenteral nutrition and drug delivery for many years [10,11]. In recent years, NEs have been significantly interested by several research groups and pharmaceutical industry due to their ease of production, high biocompatibility and suitability for targeting and modifying release profiles of actives [[9], [10], [11]].
A preliminary study was attempted for optimization of EP loaded NEs to achieve better therapeutic performance of the drug in hypertensive attacks or crisis [12]. In this complementary study, physical stability of NEs at different thermal conditions and pharmacokinetic properties of EP loaded NEs were investigated.
Section snippets
Materials
Eplerenone (EP) was kindly donated by Neutec Pharmaceuticals (Turkey), CremerCOOR® OE (oleyl erucate) (OE) was donated by Cremer Oleo GmbH & Co. KG (Germany). Brij® 35, Tween® 80 and Poloxamer® 407 were supplied by Sigma-Aldrich (Germany). Tego Care® 450 was supplied by Evonik (Germany). Other chemicals used in this study were of analytical grade.
Preparation of NEs
NEs were prepared by using high shear homogenization and ultrasonication methods [9,12]. OE, Brij® 35, Tween® 80, Tego Care® 450 and Poloxamer® 407
Physical stability
NEs of EP were obtained with high drug payload by design of experiments approach for determination of water, oil and surfactant rates in our previous study (Table 1) [12]. Those formulations were further subjected to a physical stability assessment. Droplet size of formulations was determined to increase with an increase in storage temperature for 120 days (Fig. 2 and Table 2). TegoCare® 450 and Poloxamer® 407 at rates of 1% and 2% failed to protect NEs (TC3 and P1) versus 8% and 5% oil
Conclusion
Eplerenone nanoemulsions were optimized having 200 nm ≥ droplet size with high drug payload for subcutaneous administration by design of experiments approach. Nanoemulsions stabilized with Brij® 35, Tween® 80 and Tego Care® 450 displayed good physical stability at least at 2 thermal conditions (4 ± 2 °C and 25 ± 2 °C) for 120 days of storage. 40 ± 2 °C was observed not to be suitable storage temperature for formulations containing 7% and 8% oil phase stabilized with 2% Brij® 35 and Tween® 80,
Conflicts of interest
The authors are responsible for the content of this paper report no conflicts of interest.
Acknowledgement
The present work was supported by the Research Fund of Istanbul University (Project No: TDK-2016-20429).
The bioanalytical method development and validation part of present study was presented as a poster in 10th Aegean Analytical Chemistry Days (Çanakkale, Turkey, September 29 – October 2, 2016).
We would like to thank Prof. Dr. Bayram Yılmaz from Yeditepe University, Faculty of Medicine, Department of Physiology for his valuable advices on in vivo studies. Also we would like to thank Emre
References (42)
- et al.
Mineralocorticoid receptor antagonists, a class beyond spironolactone - focus on the special pharmacologic properties of eplerenone
Int. J. Cardiol.
(2015) - et al.
Eplerenone in chronic heart failure with depressed systolic function
Int. J. Cardiol.
(2015) - et al.
Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone
Int. J. Cardiol.
(2015) - et al.
Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis
Int. J. Cardiol.
(2014) - et al.
Lipid nanoparticles for parenteral delivery of actives
Eur. J. Pharm. Biopharm.
(2009) - et al.
Drug delivery and drug targeting with parenteral lipid nanoemulsions - a review
J. Contr. Release
(2016) - et al.
Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat
J. Pharmacol. Sci.
(2008) - et al.
Comparison of seven different anesthesia protocols for nicotine pharmacologic magnetic resonance imaging in rat
Eur. Neuropsychopharmacol
(2016) - et al.
Development and validation of RP-HPLC method for estimation of eplerenone in spiked human plasma
J. Pharm. Anal
(2012) - et al.
PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Comput. Meth. Progr. Biomed.
(2010)
Influence of the introduction of a solubility enhancer on the formulation of lipidic nanoparticles with improved drug loading rates
Eur. J. Pharm. Biopharm.
Ostwald ripening in emulsions
Adv. Colloid Interface Sci.
Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice
Int. J. Pharm.
Self nanoemulsifying drug delivery system (SNEDDS) of Rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. Colloids Surf
B Biointerfaces
Nanoemulsion enhances a-tocopherol succinate bioavailability in rats
Int. J. Pharm.
Treatment blood pressure targets for hypertension
Cochrane Database Syst. Rev.
Eplerenone for hypertension
Cochrane Database Syst. Rev.
Clinical pharmacokinetics of drugs in patients with heart failure: an update (Part 2, Drugs administered orally)
Clin. Pharmacokinet.
Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug Carrier systems
Pharmazie
The design of emulsions and their fate in the body following enteral and parenteral routes
Soft Matter
Eplerenone nanoemulsions for treatment of hypertension. Part I: experimental design for optimization of formulations and physical characterization
J. Drug Deliv. Sci. Technol.
Cited by (10)
The enzymatic modification of phospholipids improves their surface-active properties and the formation of nanoemulsions
2023, Biocatalysis and Agricultural BiotechnologyDesign of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia
2019, Materials Science and Engineering CCitation Excerpt :However, CLX-NE was stable under all thermal conditions. Slight changes in this formulation might be attributed to Ostwald ripening of droplets [31]. Drug peaks were detected in DSC thermograms of CLX-SLN and CLX-NLC in consequence of the presence of drug crystals in the nanoparticle structure (Fig. 4).
Physical and chemical stability of β-carotene nanoemulsions during storage and thermal process
2019, Food Research InternationalCitation Excerpt :Ostwald ripening is the main process that dominates the destabilization of nanoemulsions. By plotting the droplet radius cubed (r3) as a function of time (t) and applying a linear regression, it is possible to calculate the speed of growth of the size of the drops as can be seen in Table 2 (Özdemir, Çelik, Sümer, Acar, & Üner, 2018), there were no differences (p > .05) in the evolution of the droplet size (Ostwald ripening rate) between temperatures of 4 and 25 °C for the nanoemulsions with the same β-carotene concentration. The concentration of active ingredient can affect the particle size (Badawy, Saad, Tayeb, Mohammed, & Abd-Elnabi, 2017); however, this was not observed in the present work, and no difference (p > .05) was found when the four conditions (0.2 and 0.5 mg mL−1 β-carotene, storage at 4 and 25 °C) were compared.
A Review on Progressive Trends in Pharmaceutical Nano Emulsions and their Assessment
2022, Research Journal of Pharmacy and TechnologyEplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends
2022, British Journal of Clinical Pharmacology